GCP
EWTX icon

GSA Capital Partners’s Edgewise Therapeutics EWTX Stock Holding History

GSA Capital Partners’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.81M Buy
+44,466
New +$1.53M 0.11% 203
2026
Q1 		– Sell
-14,085
Closed -$350K – 1853
2025
Q4 		$350K Sell
14,085
-99,158
-88% -$1.99M 0.03% 1078
2025
Q3 		$1.84M Buy
113,243
+85,967
+315% +$1.22M 0.15% 105
2025
Q2 		$358K Buy
+27,276
New +$393K 0.03% 1154
2025
Q1 		– Sell
-11,593
Closed -$310K – 1774
2024
Q4 		$310K Buy
+11,593
New +$369K 0.02% 1183
2024
Q2 		– Sell
-74,511
Closed -$1.36M – 1741
2024
Q1 		$1.36M Buy
74,511
+21,851
+41% +$347K 0.11% 263
2023
Q4 		$576K Buy
52,660
+8,696
+20% +$61.1K 0.05% 703
2023
Q3 		$252K Buy
+43,964
New +$299K 0.02% 1176
2023
Q1 		– Sell
-26,367
Closed -$236K – 1591
2022
Q4 		$236K Sell
26,367
-1,021
-4% -$9.57K 0.03% 1084
2022
Q3 		$269K Buy
27,388
+10,076
+58% +$102K 0.04% 1003
2022
Q2 		$138K Buy
+17,312
New +$131K 0.02% 1167

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GSA Capital Partners's EWTX Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Edgewise Therapeutics (EWTX) in Q2 2026: 44,466 shares worth $1.81M. The stake represents 0.11% of the portfolio and ranks #203 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in EWTX as recently as Q4 2025.

GSA Capital Partners first reported a position in EWTX in Q2 2022 and has held it in 11 quarters since. The position peaked at $1.84M in Q3 2025. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • GSA Capital Partners held 44,466 shares of Edgewise Therapeutics worth $1.81M as of Q2 2026.
  • Edgewise Therapeutics was a new GSA Capital Partners position in Q2 2026.
  • Edgewise Therapeutics made up 0.11% of GSA Capital Partners's portfolio in Q2 2026, its #203 holding.
  • GSA Capital Partners first reported a position in Edgewise Therapeutics in Q2 2022 and has held it in 11 quarters since.
  • GSA Capital Partners's Edgewise Therapeutics position peaked at $1.84M in Q3 2025.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.